×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KURA – kura oncology, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KURA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/9
07:42 am
kura
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 [Yahoo! Finance]
Low
Report
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 [Yahoo! Finance]
4/9
07:30 am
kura
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Low
Report
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
4/3
07:30 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/24
01:27 pm
kura
Kura Oncology (KURA) had its price target lowered by Mizuho from $30.00 to $25.00. They now have an "outperform" rating on the stock.
Low
Report
Kura Oncology (KURA) had its price target lowered by Mizuho from $30.00 to $25.00. They now have an "outperform" rating on the stock.
3/13
01:01 pm
kura
Kura Oncology (KURA) had its "buy" rating reaffirmed by UBS Group AG.
Low
Report
Kura Oncology (KURA) had its "buy" rating reaffirmed by UBS Group AG.
3/12
04:07 pm
kura
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/8
08:34 am
kura
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets [Yahoo! Finance]
Medium
Report
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets [Yahoo! Finance]
3/6
08:55 am
kura
Kura Oncology (KURA) had its price target lowered by Wedbush from $38.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Kura Oncology (KURA) had its price target lowered by Wedbush from $38.00 to $36.00. They now have an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:45 pm
kura
Form ARS Kura Oncology, Inc. For: Dec 31
Low
Report
Form ARS Kura Oncology, Inc. For: Dec 31
4/10
04:35 pm
kura
Form DEFA14A Kura Oncology, Inc.
Low
Report
Form DEFA14A Kura Oncology, Inc.
4/10
04:25 pm
kura
Form DEF 14A Kura Oncology, Inc. For: Jun 04
Low
Report
Form DEF 14A Kura Oncology, Inc. For: Jun 04
3/27
10:21 am
kura
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: VANGUARD GROUP INC
3/25
09:00 am
kura
Form 4 Kura Oncology, Inc. For: Mar 23 Filed by: WILSON TROY EDWARD
Medium
Report
Form 4 Kura Oncology, Inc. For: Mar 23 Filed by: WILSON TROY EDWARD
3/20
09:00 am
kura
Form 4 Kura Oncology, Inc. For: Mar 18 Filed by: Malley Thomas
Low
Report
Form 4 Kura Oncology, Inc. For: Mar 18 Filed by: Malley Thomas
3/5
07:31 am
kura
Form 10-K Kura Oncology, Inc. For: Dec 31
Medium
Report
Form 10-K Kura Oncology, Inc. For: Dec 31
3/5
06:35 am
kura
Form 8-K Kura Oncology, Inc. For: Mar 05
Low
Report
Form 8-K Kura Oncology, Inc. For: Mar 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock.
41.3%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
TOP News Decliners
3/17
Kura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - Slideshow [Seeking Alpha]
-14.5%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: